Igentify

Igentify is a digital health company and the developer of the Digital Genetic Counselor, a digital platform for genetic test providers. The platform provides a fully scalable end-to-end genetic counseling solution for both clinical and non-clinical (direct-to-consumer) genetic testing applications. The Igentify platform is developed for a variety of genotyping technologies, including microarray and next-generation sequencing (NGS), and can be customized to a broad spectrum of genetic or genomic tests offered by the test providers. The platform provides consumers with an exceptional user experience, from enrollment and personalized consent for the genetic test to the automated delivery of machine-generated personalized genetic counseling. In January 2019, Igentify was selected by Deloitte as one of the Israeli start-ups at the forefront of the digital R&D revolution.

Igentify has raised $38.36M in total funding across 8 rounds. The company is currently at the B stage. Key investors include LIP Ventures, OurCrowd, aMoon Fund.

Igentify was founded in 2016 by Doron Behar (Co-founder & CEO), Galit Delmar (Co-founder & VP Products).

Igentify operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, Patient Engagement, with core technologies in Platforms & Interfaces, Software. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients, Laboratories.

Igentify is based in Khalamish St 14, Caesarea, Israel, Center District. The company also has offices abroad.